S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

$3.00
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$2.97
$3.18
50-Day Range
$2.99
$7.85
52-Week Range
$1.71
$8.48
Volume
161,033 shs
Average Volume
208,662 shs
Market Capitalization
$40.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

CASI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.0% Upside
$12.00 Price Target
Short Interest
Healthy
2.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.29mentions of CASI Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Medical Sector

218th out of 939 stocks

Biological Products, Except Diagnostic Industry

27th out of 150 stocks

CASI stock logo

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Stock Price History

CASI Stock News Headlines

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
CASI Apr 2024 2.500 call
CASI Mar 2024 10.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
CASI Mar 2024 7.500 put
CASI Pharmaceuticals Inc CASI
CASI Pharmaceuticals Posts Narrower Loss In Q3
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/27/2024
Next Earnings (Confirmed)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CASI
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+300.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-87.15%

Debt

Sales & Book Value

Annual Sales
$43.11 million
Book Value
$3.28 per share

Miscellaneous

Free Float
10,537,000
Market Cap
$40.14 million
Optionable
Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Wei-Wu He Ph.D. (Age 59)
    Chairman & CEO
    Comp: $565.36k
  • Dr. Wei Zhang Ph.D. (Age 64)
    President
    Comp: $1.13M
  • Dr. Alexander A. Zukiwski M.D. (Age 67)
    Executive VP & Chief Medical Officer
    Comp: $514.79k
  • Ms. Kun Qian (Age 42)
    VP & Global Controller
  • Ms. Chunhua Wang (Age 52)
    Chief Operating Officer
  • Ms. Wei Gao (Age 43)
    General Counsel
  • Dr. James E. Goldschmidt Ph.D.
    Chief Business Development Officer
  • Mr. Hai Huang
    Global Chief Commercial Officer
  • Ms. Amanda Cui
    VP & Global Controller

CASI Stock Analysis - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price target for 2024?

1 brokers have issued twelve-month price targets for CASI Pharmaceuticals' stock. Their CASI share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2024?

CASI Pharmaceuticals' stock was trading at $7.16 on January 1st, 2024. Since then, CASI shares have decreased by 58.1% and is now trading at $3.00.
View the best growth stocks for 2024 here
.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 127,300 shares, an increase of 204.5% from the February 29th total of 41,800 shares. Based on an average trading volume of 194,700 shares, the days-to-cover ratio is presently 0.7 days. Approximately 2.2% of the company's stock are short sold.
View CASI Pharmaceuticals' Short Interest
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative net margin of 95.24% and a negative trailing twelve-month return on equity of 110.90%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals shares reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang and Wei-Wu He.
View institutional ownership trends
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CASI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners